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Abstract
Discontinuation of reflex testing stool submitted for Clostridium difficile testing for vancomycin-
resistant enterococci (VRE) led to an increase of patients with healthcare-associated VRE 
bacteremia and bacteriuria (2.1 versus 3.6 per 10,000 patient days; p<0.01 ). Cost-benefit analysis 
showed reflex screening and isolation of VRE reduced hospital costs.
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Introduction
Vancomycin-resistant enterococci (VRE) cause infections that result in increased cost and 
hospital length of stay (1). Previous studies reported a substantial proportion of patients with 
Clostridium difficile infection who are co-colonized with VRE (2,3). Based on these data, a 
“reflex” testing program was initiated at our hospital in the 1990’s to limit VRE 
transmission. Reflex testing was defined as any stool submitted to the laboratory for C. 
difficile toxin testing from an inpatient was also tested for VRE, using selective media (VRE 
Agar, Remel, Lenexa, KS). Patients identified as being VRE colonized or infected by reflex 
testing, routine clinical cultures, or records from an outside facility, were placed on contact 
precautions.
In 2010, concerns were raised about the cost-benefit of reflex testing. Healthcare-associated 
VRE rates both within the hospital and nationally over the previous decade had been stable 
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(4,5). Based on lack of clear evidence that reflex testing was affecting VRE epidemiology, it 
was discontinued. The purpose of this study is to examine the effect of discontinuation of 
this VRE reflex testing program on healthcare-associated VRE transmission.
Methods
Barnes-Jewish Hospital is a 1,250 bed academic tertiary care hospital in Saint Louis, 
Missouri. There are 1,160 patient rooms, of which 741 can be semi-private. Hospital policy 
is to place VRE colonized or infected patients in contact precautions in a private room. 
Reflex testing for VRE was discontinued in July 2010. Physicians were notified of this 
change. Clinicians could still order stool or peri-rectal cultures for VRE testing at their 
discretion. No additional interventions targeting VRE were implemented at the time.
To determine the effect of discontinuing reflex testing on VRE transmission, the healthcare-
associated VRE rate was evaluated from January 2009 to December 2011. All hospitalized 
patients with a positive urine or blood culture for VRE were identified. A healthcare-
associated VRE case was defined as the first positive specimen per patient, where VRE was 
detected in blood or urine > 48 hours after admission. A VRE case was considered present 
on admission if VRE first was detected in blood or urine ≤ 48 hours after admission. VRE 
cases were expressed per 1,000 patient-days.
Rate trends were evaluated using interrupted time series modeling (SPSS version 18.0; IBM 
SPSS, Chicago, IL). Segmented regression analysis was performed to assess the effect of the 
discontinuing VRE reflex testing on healthcare-associated VRE rates (6). We hypothesized 
that there would be a delay between discontinuation of the testing and resulting change in 
acquisition rates, as the effect of increased colonization pressure would not be immediately 
seen (7). Therefore, we utilized a one-month delay for evaluating the post-discontinuation 
segment. Monthly VRE prevalence on hospital admission was included in the model to 
account for any change during the study period. Institutional review board approval was 
obtained from Washington University.
Results
In the 18 months prior to discontinuation of reflex testing, 9,652 stool specimens underwent 
VRE testing (mean 536 per month). In the 18 months after reflex testing was stopped, 2,974 
stool specimens were tested (mean 165 per month; −62% difference; p <0.01). The monthly 
mean number of patients with a VRE-positive stool culture decreased from 136 to 45 (−67% 
difference; p <0.01).
There were 92 cases of healthcare-associated VRE during 433,855 patient (pt) days 
(0.21/1,000 pt days) in the reflex testing period, versus 159 cases in the 444,092 pt days 
after discontinuation (0.36/1,000 pt days) (Figure). The full regression model showed no 
baseline trend in healthcare-associated VRE (p=0.772), and no trend change after 
discontinuation of reflex testing (p=0.727). There was no significant trend in rates of VRE 
present on hospital admission (0.16 before versus 0.22 cases per 1,000 patient-days after 
discontinuation; p=0.704). There was a significant change in the y-intercept, with the 
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monthly healthcare-associated VRE rate increasing by 0.17 cases per 1,000 patient days 
(p=0.04) when VRE reflex testing was discontinued.
The cost-benefit analysis was completed for the first 12 months postdiscontinuation. 
Assuming reflex testing had been continued and the rate of healthcare-associated VRE was 
the same as the pre-intervention rate, we would have expected 14 fewer patients with VRE 
bacteremia and 26 fewer patients with bacteriuria. During the discontinuation period, the 
institution saved $20,920 in laboratory costs ($4 per VRE test, 5230 fewer tests). Isolation 
bed avoidance saved approximately $95,788 ($77 per isolation bed-day, 1,244 fewer VRE 
isolation days). Based on estimates in the literature (1) the cost of treating the excess VRE 
bacteremias was approximated at $139, 286 ($9,949/ bacteremia, 14 excess bacteremias), 
resulting in an excess cost of at least $22,578 per year without reflex testing.
Conclusion
The role of routine active surveillance in the control of antimicrobial resistant organisms in 
hospitals remains unclear (8,9). Previous studies have demonstrated the benefit of active 
surveillance cultures to control VRE transmission in hospitals, however, these were 
generally done during an outbreak in which multiple interventions were introduced 
simultaneously (10,11). We found that discontinuation of reflex VRE testing of stool 
submitted for testing for C. difficile resulted in an approximately 71% increase in the 
endemic healthcare-associated VRE rate. Strengths of the study are no other infection 
prevention measures were implemented when reflex testing was stopped, and that the VRE 
rate was stable prior to discontinuation. We hypothesize that the discontinuation of VRE 
reflex testing resulted in decreased identification and isolation of patients with VRE 
colonization, resulting in increased VRE colonization pressure throughout the hospital, and a 
subsequent increased risk of VRE transmission.
The cost of laboratory testing was a consideration in the decision to discontinue the VRE 
reflex testing program. Microbiological cultures performed on inpatients for the purpose of 
screening cannot be submitted to Medicare for reimbursement. Therefore, the cost of active 
surveillance must be absorbed by the facility. Our cost analysis suggests that savings gained 
from reduced laboratory and isolation bed cost were nullified by the increased cost of 
treating patient VRE bacteremia.
There are limitations to this study. We used a quasi-experimental study design. Therefore, 
we cannot rule out the possibility that unmeasured variables, such as underlying patient 
characteristics, may have changed during the study period and affected our findings. The 
VRE rate increased when reflex testing was discontinued even after controlling the data for 
incoming colonization pressure (i.e., patients who had VRE detected in blood or urine 
within 48 hours of admission). Laboratory methods for identifying VRE from urine and 
blood cultures did not change during the study period. This study was done in a large 
academic medical facility and the results may not be generalizable to other healthcare 
facilities with differing endemic VRE rates. We did not determine the cost associated with 
the treatment of VRE infections, other than bacteremia, though we would anticipate that 
these would further increase the cost-benefit of reflex testing. Finally, we examined cost 
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from a hospital, rather than a societal perspective, though hospitals bear the direct cost of an 
active surveillance program.
In conclusion, we found that discontinuation of reflex testing of stool submitted to the 
laboratory for C. difficile testing for VRE resulted in a hospital-wide increase in healthcare-
associated VRE and was not cost-effective. Based on these results, reflex testing was re-
instituted in at our facility. Additional studies in a variety of healthcare facilities are needed 
to determine if this screening strategy is effective in other settings.
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Figure. 
Monthly incidence of healthcare-associated vancomycin resistant enterococci (VRE), 
January 2009 - December 2011
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